MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE.

Published in:

Hematological Oncology, 2017, v. 35, p. 216, doi. 10.1002/hon.2438_80

By:

• Pott, C.;
• Belada, D.;
• Danesi, N.;
• Fingerle ‐ Rowson, G.R.;
• Gribben, J.;
• Harbron, C.G.;
• Hoster, E.;
• Kahl, B.S.;
• Kehden, B.;
• Mundt, K.E.;
• Nicolas ‐ Virelizier, E.;
• Sehn, L.H.;
• Cheson, B.D.

Publication type:

Article